Sarepta says yet to receive new date for panel review of muscle wasting drug

(Reuters) - Drug developer Sarepta Therapeutics Inc said it had not received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and would slash about 17 percent of its workforce.

http://ift.tt/1Sy7bvS

from Reuters: Health News
via animenewspro